| Ticker Details |
TG Therapeutics, Inc.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
|
| IPO Date: |
June 1, 2010 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$5.95B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.46 | 3.11%
|
| Avg Daily Range (30 D): |
$0.84 | 2.26%
|
| Avg Daily Range (90 D): |
$0.66 | 2.02%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.49M |
| Avg Daily Volume (30 D): |
1.76M |
| Avg Daily Volume (90 D): |
1.71M |
| Trade Size |
| Avg Trade Size (Sh.): |
115 |
| Avg Trade Size (Sh.) (30 D): |
69 |
| Avg Trade Size (Sh.) (90 D): |
70 |
| Institutional Trades |
| Total Institutional Trades: |
6,042 |
| Avg Institutional Trade: |
$2.91M |
| Avg Institutional Trade (30 D): |
$3.93M |
| Avg Institutional Trade (90 D): |
$3.98M |
| Avg Institutional Trade Volume: |
.14M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.24M |
| Avg Closing Trade (30 D): |
$10.16M |
| Avg Closing Trade (90 D): |
$9.39M |
| Avg Closing Volume: |
264.63K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$3.22
|
$.14
|
$.2
|
|
Diluted EPS
|
$2.87
|
$.12
|
$.15
|
|
Revenue
|
$700.35M
|
$204.92M
|
$192.57M
|
|
Gross Profit
|
$581.67M
|
$171.41M
|
$154.43M
|
|
Net Income / Loss
|
$461.9M
|
$19.78M
|
$23.04M
|
|
Operating Income / Loss
|
$149.5M
|
$34.8M
|
$50.49M
|
|
Cost of Revenue
|
$118.68M
|
$33.51M
|
$38.14M
|
|
Net Cash Flow
|
$310.12M
|
$363.07M
|
$5.08M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Apr 30, 2012
|
5:281
|
|
Jul 14, 2011
|
1:50
|
|
Sep 25, 2003
|
1:5
|
|
|
|
